Trial · NCT06174922
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
NCT06174922, Phase 3, Recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis. Trials, record NCT06174922. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06174922
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
- NCT number
- NCT06174922
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- Interventions
- Prednisolone, Itraconazole
- First posted
- 2023-12-18
- Last updated
- 2025-02-28
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Asthma or ABPA exacerbations | 12 months after treatment completion | Proportion of subjects experiencing exacerbation (asthma or ABPA) 12 months after treatment completion |
| Secondary | Composite response | 8 weeks | Proportion of subjects experiencing composite response defined as symptomatic improvement by at least 50%; and, major radiological improvement, and a decline in serum total IgE by at least 20% of baseline |
| Secondary | IgE decline | 8 weeks | Percentage decline in IgE (baseline IgE minus IgE after eight weeks/baseline IgE |
| Secondary | Time to first ABPA exacerbation | 12 months after treatment completion | Time to first ABPA exacerbation in days |
| Secondary | Time to first asthma exacerbation | 12 months after treatment completion | Time to first asthma exacerbation in days |
| Secondary | Weight gain | Two months | Treatment-related adverse effects |
| Secondary | Hyperglycemia | Two months | Treatment-related adverse effects |
| Secondary | Cushingoid habitus | Two months | Treatment-related adverse effects |
| Secondary | Transaminitis | Two months | Treatment-related adverse effects |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06174922
GET https://conductscience.org/api/trials/v1/NCT06174922/registered